The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
Patients with locally advanced or metastatic UC who are ineligible for cisplatin-containing ChT and have previously received ≥1 prior lines of therapy
Genitourinary Cancers
Urothelial Carcinoma
-
EV-201 - Cohort 2
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Erdafitinib
-
Single arm (Phase II)
Locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations and disease progression during/after ≥1 prior platinum-containing ChT
Genitourinary Cancers
Urothelial Carcinoma
FGFR3 or FGFR2 genetic alterations
BLC2001
1
PRELIMINARY SCORE
OS
7
ADJUSTMENTS
FINAL SCORE
F1
5
Pembrolizumab
-
Single arm (Phase II)
Locally advanced or metastatic UC in adults who are not eligible for cisplatin-containing ChT and whose tumours express PD-L1 with a CPS ≥10
Genitourinary Cancers
Urothelial Carcinoma
PD-L1 CPS ≥10%
MK-03475-052/KEYNOTE-052
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Pembrolizumab
-
Investigator’s choice of ChT (paclitaxel, docetaxel or vinflunine)
Locally advanced or metastatic UC in adults who have received prior platinum-containing ChT
Genitourinary Cancers
Urothelial Carcinoma
-
MK-3475-045/KEYNOTE-045
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
Nivolumab
-
Placebo
Adjuvant therapy for adult patients with oesophageal or gastroesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy
Gastrointestinal Cancers
Oesophageal or gastroesophageal carcinoma
-
CheckMate 577
A
ADJUSTMENTS
FINAL SCORE
F1
1
Sotorasib
-
Single arm
Treatment of adults with advanced non-small cell lung cancer with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy
Thoracic Malignancies
Non-small-cell Lung Cancer
KRAS G12C mutated
CodeBreaK 100
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Cemiplimab
-
Single arm (Phase II)
Treatment of basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI)
Skin Cancers
Basal Cell Carcinoma
-
Study 1620
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Nivo/Ipi (nivolumab and ipilimumab)
-
Single arm (Phase II)
Adult patients with MMR-deficient or MSI-high mCRC after prior fluoropyrimidine-based combination ChT
Gastrointestinal Cancers
Colorectal Cancer
dMMR or MSI-H
CheckMate142
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Pemetrexed
Cisplatin
Cisplatin
In combination with cisplatin for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma
Thoracic Malignancies
Pleural mesothelioma
-
EMPHACIS
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Lenvatinib
Pembrolizumab
Sunitinib
Treatment of adults with advanced renal cell carcinoma in combination with pembrolizumab as first-line treatment
Genitourinary Cancers
Renal cell cancer
-
CLEAR
4
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
2
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Treatment Setting
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
esmo.mcbs.table.heading.visualisation
esmo.mcbs.table.heading.visualisation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.